Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III-India and Switzerland)

Next Previous
Trial Profile

GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III-India and Switzerland)

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 20 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabigatran etexilate (Primary)
  • Indications Pulmonary embolism; Stroke; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GLORIA-AF
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 01 Feb 2025 Results (n=10,594) assessing the effect of renal function on the occurrence of clinical adverse events by comparing NOAC and VKA treatment (GLORIA-AF global registry) published in the Journal of Thrombosis and Thrombolysis.
  • 01 Jan 2024 Results of pooled analysis from NCT01468701, NCT01671007 and NCT01937377; evaluating the predictive ability of the 2MACE score published in the Journal of Thrombosis and Thrombolysis
  • 01 Jan 2024 Results demonstrating antithrombotic effect of dabigatran and vitamin K antagonist in Patients with Atrial Fibrillation, published in the American Journal of Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top